Molecules of the brain.
Progress against a range of brain disorders is being sustained by the use of genetic research techniques to identify specific molecules involved in brain disease, and by the realization that the identified molecules may disclose novel therapeutic targets. Both strategies are illustrated by recent insights and interventions in Alzheimer's disease and Parkinson's disease.
Levey
A I
AI
Emory University School of Medicine, Atlanta, USA.
D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D001923:Brain Chemistry / Q000235:genetics* / Q000502:physiology*; D005826:Genetics, Medical; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D008967:Molecular Biology; D009154:Mutation / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000235:genetics; D010300:Parkinson Disease / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D010597:Pharmacogenetics; D053764:Presenilin-1; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000235:genetics; D011954:Receptors, Dopamine / Q000187:drug effects / Q000235:genetics; D017470:Receptors, Glutamate / Q000187:drug effects / Q000235:genetics; D051843:Synucleins
D016564:Amyloid beta-Protein Precursor; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; C508853:PSEN1 protein, human; D053764:Presenilin-1; D011950:Receptors, Cholinergic; D011954:Receptors, Dopamine; D017470:Receptors, Glutamate; D051843:Synucleins